Beijing Enze Kangtai Biotechnology

The company's operations are divided into two main segments. The first involves providing CRO and CDMO services for exosome innovative drug research and development, which includes carrier design and development of engineered exosome drugs. The second segment focuses on translational medicine research services centered around basic exosome research, carried out in collaboration with clinical experts. The business model generates revenue through these contract research and manufacturing services, as well as by providing exosome-related products and comprehensive research solutions to scientific institutions. Its client base includes over 100 major hospitals and scientific research units in China, along with various biopharmaceutical and precision medicine companies.

ECHO Biotech has developed three core platforms: Exoomics®, a multi-omics platform for hospitals and research institutions; Echosome®, an engineered exosome platform offering CRO services for drug development to biopharmaceutical companies; and EchoPharm®, which provides CDMO services and raw material production. The company's R&D pipeline targets areas such as tumor immunity, rare diseases, and neurological disorders. For instance, in rare disease treatment, it employs exosome-based protein replacement therapy. A significant milestone was achieved when its subsidiary, Beijing Enkang Pharmaceutical Co., Ltd., received both a US FDA Drug Master File (DMF) and an International Nomenclature of Cosmetic Ingredients (INCI) registration for its human mesenchymal stem cell exosome raw material, GoldenExo®. The company has successfully raised multiple rounds of funding, including an A+ round led by Baidu Ventures and an A++ round in March 2023, to advance its technology platforms and accelerate clinical applications.